Jefferies Group reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday morning. They currently have a GBX 5,500 ($74.59) target price on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. UBS Group set a GBX 4,550 ($61.70) price target on AstraZeneca and gave the stock a neutral rating in a research note on Monday, January 8th. Morgan Stanley set a GBX 4,700 ($63.74) price target on AstraZeneca and gave the stock a neutral rating in a research note on Friday, October 20th. Deutsche Bank reiterated a buy rating and set a GBX 5,600 ($75.94) price target on shares of AstraZeneca in a research note on Wednesday, October 11th. JPMorgan Chase & Co. set a GBX 4,500 ($61.03) price target on AstraZeneca and gave the stock a neutral rating in a research note on Wednesday, October 18th. Finally, Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, October 23rd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of GBX 5,219 ($70.78).
AstraZeneca (LON:AZN) opened at GBX 5,043 ($68.39) on Tuesday. AstraZeneca has a 52 week low of GBX 4,136.50 ($56.10) and a 52 week high of GBX 5,520 ($74.86). The company has a market capitalization of $63,860.00 and a PE ratio of 2,508.96.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.